United States Patent 7,727,984: Scope, Claim Construction, and US Landscape for the Benzo[1,4]Oxazin-3-one Series
What does US 7,727,984 claim cover, at the molecule level?
US 7,727,984 has four independent/dependent claims that together define a single chemical structure family centered on R-6-Hydroxy-8-substituted 4H-benzo[1,4]oxazin-3-one plus permitted forms (acid salts, hydrates, and solvates). The claims are narrow at the core structure and broaden only in the form-of-matter sense (salts and hydrates/solvates).
Core compound motif (claims 1, 2, 4)
All operative claims share the same defined chemical entity:
R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one
Key structural constraints embedded in the claim language:
- Stereochemistry: “R-6-hydroxy” (the 6-position hydroxy is explicitly R-configured).
- Ring system: 4H-benzo[1,4]oxazin-3-one core.
- Substitution pattern at position 8:
- 1-hydroxy-2-[...]-ethyl chain motif
- Terminal anilide-like dialkylamino fragment: “2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino”
- Functional “form” allowances: acid addition salts, solvates, hydrates.
Form-of-matter coverage
- Claim 1 (broadest “form” claim): compound or acid addition salt (pharmaceutically acceptable acid) or solvate or hydrate.
- Claim 2: the free base (the exact stereodefined structure).
- Claim 3: an acid addition salt of claim 2 with a pharmacologically acceptable acid.
- Claim 4: compound or acid addition salt or hydrate.
Claim 1 vs Claim 4: both cover compound + acid salts + hydrates; Claim 1 additionally includes solvates as a covered form (Claim 4 omits solvate language). This makes Claim 1 the most defensible hook for intermediate/processing-derived solvated forms.
What is actually “in scope” for competitors under US 7,727,984?
The scope breaks into two practical infringement routes: (i) structural identity and (ii) permitted pharmaceutical forms.
1) Structural identity gate
To fall within the claimed compound, an accused product or intermediate must match the full structure set in the claim:
- The same benzo[1,4]oxazin-3-one scaffold
- The same substitution pattern at 6 and 8
- The same “R” stereochemistry at the 6-hydroxy position
- The same side chain architecture, including:
- the 2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino motif
Any change to:
- substitution positions,
- ring atoms,
- stereochemistry (R at 6),
- aryl substituent pattern (the 4-methoxy is literal),
- the terminal amino substituent pattern (literal “1,1-dimethyl” and “ethylamino” motif),
is an argument for non-infringement on claim language.
2) Form-of-matter gate
Even if the free base matches, infringement analysis depends on the form:
- Acid addition salts are explicitly within scope, but only for pharmacologically acceptable acids.
- Hydrates are explicitly within scope (claims 1 and 4).
- Solvates are explicitly within scope only in claim 1.
For lifecycle tactics:
- If a manufacturer markets or supplies a specific hydrate or specific solvate, Claim 1 and/or Claim 4 may be triggered depending on the form.
- If only an anhydrous free base is used, Claims 2 and 4 remain relevant (Claim 1 also covers it).
What do the claims imply about composition and “method” risk?
US 7,727,984, based on the provided claim set, is form-of-matter chemical coverage rather than a method-of-treatment claim set.
- There is no claim language here that binds to dosing regimens, routes of administration, patient selection, or therapeutic use.
- The risk focus is manufacture, import, offer for sale, or sale of the claimed compound or its covered forms.
This matters because it limits arguments that competitors can avoid infringement by changing therapy strategy; the primary avoidance route is chemical design-around (structure or stereochemistry) or form selection where the patent does not cover that specific form.
How would a typical claim construction read the key terms?
The following terms are the operative “limiting” elements within the claim language:
| Claim Term |
Functional meaning in scope |
Practical implication |
| “R-6-Hydroxy” |
Requires R stereochemistry at the 6-hydroxy |
Switching to S (or racemate with different presence/ratio) is an immediate design-around lever |
| “4H-benzo[1,4]oxazin-3-one” |
Requires the exact heterocycle and numbering |
Scaffold change is non-infringement unless doctrine extends beyond explicit claim language |
| “8-{...}” |
Requires the exact 8-substituted chain motif |
Changing side-chain length, linkage, or substitution pattern changes scope |
| “2-(4-methoxy-phenyl)” |
Requires para-methoxy on the phenyl ring |
Replacing 4-OMe with other substitutions is a straightforward avoidance argument |
| “1,1-dimethyl-ethylamino” |
Requires the amino substitution pattern |
Any change to gem-dimethyl or chain length likely breaks literal match |
| “acid addition salt” + “pharmacologically acceptable acid” |
Limits salts to pharmaceutically acceptable acids |
Salt selection must be evaluated against “acceptable” acids (common pharmaceutically acceptable acids are typically broad) |
| “solvate” |
Only Claim 1 explicitly covers solvates |
If a competitor uses a particular solvate form, Claim 1 has additional coverage leverage |
| “hydrate” |
Claims 1 and 4 explicitly cover hydrates |
Water content/form can become a key infringement or non-infringement point |
What is the scope relationship between Claims 1, 2, 3, and 4?
The claim set is a layered structure:
- Claim 2 is the free base.
- Claim 3 is Claim 2 converted to acid addition salts.
- Claim 4 is Claim 2 plus acid salts plus hydrates (still no solvate).
- Claim 1 is Claim 2 plus acid salts plus solvates plus hydrates.
This means:
- If an accused product is an acid salt or hydrate, both Claim 1 and Claim 4 can be asserted, with Claim 3 also available for salts.
- If an accused product is a solvate, Claim 1 is the relevant claim (Claim 4 does not include solvates).
- If an accused product is the free base, Claims 2 and 4 (and Claim 1) remain available.
US Patent Landscape: What patents are typically “paired” with this kind of claim?
A complete US landscape requires bibliographic confirmation of the patent family, assignee, priority date, and related continuations or continuation-in-part patents. That information is not provided in the prompt.
With only the claim language and patent number, the most defensible landscape statements are structural and risk-oriented rather than family-network oriented.
1) Landscape expectation for benzo[1,4]oxazin-3-one series patents
Patents in this chemical space typically cluster around:
- Core scaffold claims (exact heterocycle and substitution pattern)
- Specific stereochemistry claims (R/S or resolved enantiomers)
- Salt and solvates claims to capture manufacturing states
- Crystallization/process-dependent forms claims (polymorphs, hydrates, solvates)
- Separate filings for intermediates and processes (to control supply chain)
Given US 7,727,984 explicitly claims:
- a fully specified stereodefined molecule, and
- acid salts, hydrates, and in Claim 1, solvates,
the patent is likely positioned as a composition-of-matter anchor that is reinforced by downstream filings on forms and upstream filings on intermediates. That is the standard portfolio logic for high-value small-molecule launches.
2) Practical risk to generics and developers
For a generic or “follow-on” entrant:
- If they use the same stereochemistry and substituent pattern, they face direct claim coverage on the molecule and all covered forms.
- If they change only the salt: Claims 1 and 3 cover “acid addition salts” with pharmaceutically acceptable acids, so many common salt options will still land inside the claims.
- If they change only the crystal form: if the alternative is an anhydrous free base, Claim 2 still applies. If it is a hydrate, Claim 1/4 still apply. If it is a solvate, Claim 1 applies.
So the meaningful design-around levers are:
- stereochemistry at C6,
- substitution pattern on the aniline ring (4-methoxy),
- amino side-chain substitution (1,1-dimethyl-ethylamino),
- or a scaffold substitution that breaks the exact benzo[1,4]oxazin-3-one structure requirements.
Design-around map tied to the literal claim language
This section converts the claim into explicit “change points.”
| Literal claim constraint |
Design-around direction that breaks literal coverage |
| “R-6-hydroxy” |
Use the opposite enantiomer at 6 (S) or a non-matching stereochemical profile (including careful control of enantiomeric purity) |
| “4-methoxy-phenyl” |
Replace para-methoxy with another substituent (or change substitution pattern entirely) |
| “1,1-dimethyl-ethylamino” |
Change the gem-dimethyl motif or amino side-chain structure |
| “4H-benzo[1,4]oxazin-3-one” |
Replace the core heterocycle or change ring formation such that numbering/scaffold no longer matches |
| “8-{1-hydroxy-2-[...]-ethyl}” linkage |
Change chain length, hydroxyl position, or linkage architecture at the 8 position |
Form-only changes (switching from hydrate to anhydrous, or swapping a common acid salt to another pharmaceutically acceptable acid) are unlikely to escape because the claims cover both the free base and acid salts and hydrates, with solvates also included in Claim 1.
Key Takeaways
- US 7,727,984 is a tight, structure-defined composition-of-matter patent covering a single stereodefined molecule: R-6-hydroxy-8-(specified side chain)-4H-benzo[1,4]oxazin-3-one.
- Claims 1 and 4 cover salts and hydrates; Claim 1 also covers solvates.
- Claims 2 and 3 lock the free base and acid salts, respectively; avoiding infringement by switching between common pharmaceutically acceptable salts or hydrate/anhydrous form is unlikely to work.
- The credible design-around levers are stereochemistry and structural substituent changes that break literal matching at 6, 8, the 4-methoxy phenyl, or the 1,1-dimethyl-ethylamino side chain.
FAQs
1) Does US 7,727,984 cover only the free base or also salts and hydrates?
It covers the free base (Claim 2) and also acid addition salts (Claims 1 and 3) and hydrates (Claims 1 and 4). Solvates are covered in Claim 1.
2) Is the stereochemistry at the 6-hydroxy position a hard limitation?
Yes. The claim requires “R-6-hydroxy”, which constrains coverage to the R configuration at that specific position.
3) If a competitor makes a different hydrate crystal form, is it still within scope?
If it is a hydrate of the claimed compound, Claim 1 and/or Claim 4 apply. The claims do not limit to a specific hydrate structure, only to the hydrate form generally.
4) Can a competitor escape by switching to a different pharmaceutically acceptable acid salt?
Not if it remains an acid addition salt with a pharmacologically acceptable acid, because salts are expressly covered.
5) What is the most direct chemical design-around path?
Change one of the literal structural constraints that define the molecule: stereochemistry at 6, the 4-methoxy substituent on the phenyl ring, the 1,1-dimethyl-ethylamino motif, or the benzo[1,4]oxazin-3-one scaffold/8-substitution architecture.
References
[1] United States Patent No. 7,727,984.
